Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer
This trial is active, not recruiting.
|Sponsor||University of Oklahoma|
|Start date||October 2010|
|End date||July 2015|
|Trial size||60 participants|
|Trial identifier||NCT01580241, 2606|
The investigators believe DCAMKL-1 is a stem cell tumor marker and is elevated in patients with pancreatic cancer. The investigators would like to analyze its expression pre and post treatment, to gauge the correlation between current pancreatic cancer therapies and the expression of DCAMKL-1
Male or female participants at least 18 years old.
Inclusion Criteria: - pancreatic cancer Exclusion Criteria: - age < 18, history of other types of cancer
|Official title||Expression Patterns of Stem Cell Marker Doublecortin and CaM Kinase-Like-1 (DCAMKL-1) in Human Pancreatic Adenocarcinoma|
|Principal investigator||Courtney Houchen, MD|
Call for more information